全文获取类型
收费全文 | 60005篇 |
免费 | 6580篇 |
国内免费 | 2248篇 |
专业分类
耳鼻咽喉 | 127篇 |
儿科学 | 550篇 |
妇产科学 | 224篇 |
基础医学 | 2448篇 |
口腔科学 | 387篇 |
临床医学 | 5189篇 |
内科学 | 6745篇 |
皮肤病学 | 1043篇 |
神经病学 | 2012篇 |
特种医学 | 607篇 |
外国民族医学 | 7篇 |
外科学 | 1732篇 |
综合类 | 7914篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 3593篇 |
眼科学 | 641篇 |
药学 | 29071篇 |
26篇 | |
中国医学 | 2909篇 |
肿瘤学 | 3600篇 |
出版年
2024年 | 68篇 |
2023年 | 960篇 |
2022年 | 1158篇 |
2021年 | 2015篇 |
2020年 | 2202篇 |
2019年 | 2217篇 |
2018年 | 2265篇 |
2017年 | 2539篇 |
2016年 | 2353篇 |
2015年 | 2366篇 |
2014年 | 4011篇 |
2013年 | 6772篇 |
2012年 | 4109篇 |
2011年 | 4192篇 |
2010年 | 3372篇 |
2009年 | 2989篇 |
2008年 | 2803篇 |
2007年 | 2842篇 |
2006年 | 2560篇 |
2005年 | 2303篇 |
2004年 | 1958篇 |
2003年 | 1790篇 |
2002年 | 1361篇 |
2001年 | 1317篇 |
2000年 | 997篇 |
1999年 | 848篇 |
1998年 | 722篇 |
1997年 | 675篇 |
1996年 | 566篇 |
1995年 | 549篇 |
1994年 | 467篇 |
1993年 | 395篇 |
1992年 | 452篇 |
1991年 | 378篇 |
1990年 | 300篇 |
1989年 | 242篇 |
1988年 | 243篇 |
1987年 | 236篇 |
1986年 | 183篇 |
1985年 | 195篇 |
1984年 | 160篇 |
1983年 | 123篇 |
1982年 | 105篇 |
1981年 | 85篇 |
1980年 | 58篇 |
1979年 | 57篇 |
1978年 | 67篇 |
1977年 | 46篇 |
1976年 | 47篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Weifeng Tang Helena Engman Yali Zhu Brian Dayton David W. Boulton 《Clinical therapeutics》2019,41(8):1545-1563
PurposeFixed-combination drug products (FCDPs) for patients with type 2 diabetes mellitus (T2DM) may show efficacy comparable to their individual components (ICs) while improving adherence to treatment. This study evaluated the bioequivalence and safety of 2 dapagliflozin/saxagliptin/metformin extended-release (XR) FCDPs relative to their ICs: saxagliptin and dapagliflozin/metformin XR.MethodsThis randomized, open-label, single-dose, single-center crossover study was conducted in 84 healthy subjects aged 18–55 years. The primary objective was to evaluate the fed-state bioequivalence of a dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP and a dapagliflozin 10-mg/saxagliptin 5-mg/metformin 1000-mg XR FCDP relative to the ICs. Secondary objectives included the evaluation of the effect of food on the pharmacokinetic (PK) parameters of saxagliptin, dapagliflozin, and metformin in both FCDPs and characterization of the PK parameters of the active metabolite of saxagliptin, 5-hydroxy saxagliptin, in healthy subjects. PK parameters (AUC0–∞, AUC0–t, and Cmax) were used to assess the bioequivalence of the 2 FCDPs with their ICs. The Cmax and AUC0–t of the study drugs were compared between female and male subjects to assess sex differences in exposure. Safety and tolerability of both FCDPs and ICs were also assessed with adverse events, vital signs (systolic and diastolic blood pressures and pulse rate), 12-lead ECG, physical examinations, and laboratory assessments.FindingsBoth dapagliflozin/saxagliptin/metformin XR FCDPs were bioequivalent to their ICs. For the dapagliflozin 5-mg/saxagliptin 2.5-mg/metformin 1000-mg XR FCDP, the 90% CI for the geometric mean ratio of dapagliflozin Cmax was slightly above the 80%–125% bioequivalence limit, which is unlikely to be clinically relevant. Food delayed the absorption of the study drugs in both FCDPs, which is unlikely to have a clinically relevant impact on efficacy. In both cohorts, exposure was higher in female subjects compared with male subjects, potentially due to the lower body weight of the female subjects. The safety profile and tolerability of the FCDPs were similar to those of their ICs, and no deaths or serious adverse events were reported.ImplicationsThese data support the use of the dapagliflozin/saxagliptin/metformin XR FCDP in patients with T2DM. ClinicalTrials.gov identifier: NCT03169959. 相似文献
82.
83.
84.
Luis Hermenegildo Martín Arias Antonio Martín Gonzlez Rosario Sanz Fadrique Esther Salgueiro Vzquez 《Fundamental & clinical pharmacology》2019,33(2):134-147
Prior meta‐analyses have shown a higher gastrointestinal risk of nonselective NSAIDs versus placebo and a lower gastrointestinal risk of coxibs versus nonselective NSAIDs. However, the available data about gastrointestinal risk for coxibs versus placebo are scarce. The aim of this study was to review the current evidence on the use of coxibs and to evaluate the risk of gastrointestinal adverse outcomes (GAO) associated with coxibs versus nonexposed. Search was conducted on PubMed and Embase databases. We selected cohort observational, case‐control, nested case‐control and case‐crossover studies that reported the risk of GAO associated with coxibs versus nonexposed as relative risk (RR), odds ratio (OR), hazard ratio (HR) or incidence rate ratio (IRR). It was estimated the pooled RR and the 95% confidence interval (CI) for coxibs both individually and as a whole by the DerSimonian and Laird method. Twenty‐eight studies met inclusion criteria. Overall, coxibs were associated with a significant increment in the risk of GAO [RR 1.64 (95% CI 1.44–1.86)]. The analysis by individual drugs showed that etoricoxib [RR 4.85 (95% CI 2.64–8.93)] presented the highest gastrointestinal risk, followed by rofecoxib [RR 2.02 (95% CI 1.56–2.61)] and celecoxib [RR 1.53 (95% CI 1.19–1.97)]. Gastrointestinal risk was also high for the subgroups aged <65 years and low‐dose coxibs. The use of coxibs is associated with a statistically significant increased risk of GAO, which would be high even for low‐dose coxibs and <65‐year‐old subgroups. The risk would be higher for etoricoxib than for celecoxib and rofecoxib. 相似文献
85.
86.
目的以树状大分子为载体材料并修饰血脑屏障(blood brain barrier,BBB)靶向短肽TGN和肿瘤靶向短肽i RGD构建脑胶质瘤靶向递药系统(i RGD/TGN-PEG-PAMAM/ATO),旨在解决三氧化二砷(arsenictrioxide,As2O3,ATO)在治疗脑胶质瘤过程中分布缺乏特异性、透BBB难等问题,使其具有更好抗脑胶质瘤作用。方法核磁共振图谱(1H-NMR)、透射电子显微镜(TEM)等考察载体的理化性质;电感耦合等离子发射光谱(ICP)、透析袋法分析其包封率及体外释放情况;通过激光共聚焦及流式细胞仪分析i RGD、TGN对细胞摄取的影响;MTT法考察纳米载体对脑微血管内皮细胞(HBMEC)和脑胶质瘤U87细胞的毒性及BBB模型中递药系统抑制U87细胞生长的情况。结果成功合成了i RGD/TGN-PEG-PAMAM载体,其形态规整,大小均匀,测得其粒径(24.87±0.84)nm,电位(17.26±1.64)m V;该载体对HBMEC和U87细胞均具有较小的毒性;递药系统i RGD/TGN-PEG-PAMAM/ATO的包封率为(71.92±1.17)%,体外释放表明ATO经载体包载后呈现一种缓慢释放趋势,且在酸性条件下更有利于ATO的释放;细胞摄取结果提示iRGD/TGN的修饰有利于U87细胞对递药系统的摄取;体外跨BBB抑制U87细胞生长实验结果表明,i RGD/TGN-PEG-PAMAM/ATO组具有更好的跨BBB抑制U87细胞生长效果。结论 i RGD/TGN-PEG-PAMAM/ATO脑胶质瘤靶向递药系统具有较好的体外跨BBB抑制U87细胞生长的效果,为脑胶质瘤治疗提供了新的策略。 相似文献
87.
88.
89.
《Clínica e investigación en ginecología y obstetricia》2019,46(4):167-169
Gestational trophoblastic disease (GTD) is a group of tumours caused by the hyperproliferation of trophoblast cells and is noted for its overproduction of hCG. Among its manifestations, there may be hyperthyroidism, due to the stimulating activity of hCG on TSH receptors. In most cases it is only a biochemical hyperthyroidism, with its presentation as symptomatic hyperthyroidism being much less frequent. We report the case of a patient with GTD, who at diagnosis presented with symptomatic hyperthyroidism. Treatment included surgical evacuation of the hydatidiform mole, as well as a beta-blocker and antithyroid drug treatment to relieve the symptoms. 相似文献